Environmental modifiers of RTS,S/AS01 malaria vaccine efficacy in Lilongwe, Malawi.

Griffin J BellMatthew S LoopTisungane MvaloJonathan J JulianoInnocent MofoloPortia KamthunziGerald TeghaMarc LievensJeffrey BaileyMichael EmchIrving Hoffman

Published in: BMC public health (2020)

Efficacy of GSK Biologicals' Candidate Malaria Vaccine (257049) Against Malaria Disease Caused by P. falciparum Infection in Infants and Children in Africa. NCT00866619 prospectively registered 20 March 2009.

Keyphrases

plasmodium falciparum
young adults
signaling pathway
cell proliferation